768 related articles for article (PubMed ID: 28249894)
21. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
[TBL] [Abstract][Full Text] [Related]
22. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
[TBL] [Abstract][Full Text] [Related]
23. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
[TBL] [Abstract][Full Text] [Related]
24. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.
Bocian K; Borysowski J; Wierzbicki P; Wyzgal J; Klosowska D; Bialoszewska A; Paczek L; Górski A; Korczak-Kowalska G
Nephrol Dial Transplant; 2010 Mar; 25(3):710-7. PubMed ID: 19903662
[TBL] [Abstract][Full Text] [Related]
25. Natural and inducible Tregs in swine: Helios expression and functional properties.
Käser T; Mair KH; Hammer SE; Gerner W; Saalmüller A
Dev Comp Immunol; 2015 Apr; 49(2):323-31. PubMed ID: 25511662
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
Martin TG; Corzo K; Chiron M; Velde HV; Abbadessa G; Campana F; Solanki M; Meng R; Lee H; Wiederschain D; Zhu C; Rak A; Anderson KC
Cells; 2019 Nov; 8(12):. PubMed ID: 31779273
[TBL] [Abstract][Full Text] [Related]
27. High concentrations of atorvastatin reduce in-vitro function of conventional T and regulatory T cells.
Rodríguez-Perea AL; Rojas M; Velilla-Hernández PA
Clin Exp Immunol; 2019 May; 196(2):237-248. PubMed ID: 30638266
[TBL] [Abstract][Full Text] [Related]
28. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
[TBL] [Abstract][Full Text] [Related]
29. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.
Wu T; Zhang L; Xu K; Sun C; Lei T; Peng J; Liu G; Wang R; Zhao Y
Transpl Immunol; 2012 Aug; 27(1):30-8. PubMed ID: 22613676
[TBL] [Abstract][Full Text] [Related]
30. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
Fourtounas C; Dousdampanis P; Sakellaraki P; Rodi M; Georgakopoulos T; Vlachojannis JG; Mouzaki A
Am J Nephrol; 2010; 32(1):1-9. PubMed ID: 20484893
[TBL] [Abstract][Full Text] [Related]
31. Fine-tuning of regulatory T cell function: the role of calcium signals and naive regulatory T cells for regulatory T cell deficiency in multiple sclerosis.
Schwarz A; Schumacher M; Pfaff D; Schumacher K; Jarius S; Balint B; Wiendl H; Haas J; Wildemann B
J Immunol; 2013 May; 190(10):4965-70. PubMed ID: 23576680
[TBL] [Abstract][Full Text] [Related]
32. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
Yu Y; Huang R; Zong X; He X; Mo W
BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
[TBL] [Abstract][Full Text] [Related]
33. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S; Diallo BK; El-Murr N; Carrié N; Tang A; Fournier A; Bonnevaux H; Nicolazzi C; Cuisinier M; Arnould I; Sidhu SS; Corre J; Avet-Loiseau H; Teillaud JL; van de Velde H; Wiederschain D; Chiron M; Martinet L; Virone-Oddos A
Blood; 2022 Feb; 139(8):1160-1176. PubMed ID: 35201323
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
Scott GB; Carter C; Parrish C; Wood PM; Cook G
Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
[TBL] [Abstract][Full Text] [Related]
35. Analysis of murine and human Treg subsets in inflammatory bowel disease.
Sun X; He S; Lv C; Sun X; Wang J; Zheng W; Wang D
Mol Med Rep; 2017 Sep; 16(3):2893-2898. PubMed ID: 28677759
[TBL] [Abstract][Full Text] [Related]
36. Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro.
Podestà MA; Binder C; Sellberg F; DeWolf S; Shonts B; Ho SH; Obradovic A; Waffarn E; Danzl N; Berglund D; Sykes M
Am J Transplant; 2020 Jan; 20(1):88-100. PubMed ID: 31319439
[TBL] [Abstract][Full Text] [Related]
37. Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
Stocker N; Gaugler B; Ricard L; de Vassoigne F; Marjanovic Z; Mohty M; Malard F
Cancer Med; 2020 Mar; 9(6):2077-2084. PubMed ID: 31991058
[TBL] [Abstract][Full Text] [Related]
38. Analysis of peripheral blood T-cell subsets and regulatory T-cells in multiple myeloma patients.
Huang LQ; Wang JX; He K; Jiang YZ; Wei ZL; Huang DP; Chu LL
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):113-117. PubMed ID: 29729703
[TBL] [Abstract][Full Text] [Related]
39. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
[TBL] [Abstract][Full Text] [Related]
40. Partial CD25 Antagonism Enables Dominance of Antigen-Inducible CD25
Wilkinson DS; Ghosh D; Nickle RA; Moorman CD; Mannie MD
Front Immunol; 2017; 8():1782. PubMed ID: 29312311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
